CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Artelo Biosciences, Inc. - ARTL CFD

    1.34
    3.6%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 1.39
    Open* 1.36
    1-Year Change* -45.82%
    Day's Range* 1.3 - 1.39
    52 wk Range 0.28-1.32
    Average Volume (10 days) N/A
    Average Volume (3 months) 6.27M
    Market Cap 14.97M
    P/E Ratio -100.00K
    Shares Outstanding 42.30M
    Revenue N/A
    EPS -0.34
    Dividend (Yield %) N/A
    Beta 2.74
    Next Earnings Date Nov 11, 2022

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 7, 2023 1.39 0.03 2.21% 1.36 1.42 1.34
    Dec 6, 2023 1.40 0.04 2.94% 1.36 1.42 1.36
    Dec 5, 2023 1.42 0.03 2.16% 1.39 1.48 1.36
    Dec 4, 2023 1.41 0.01 0.71% 1.40 1.42 1.36
    Dec 1, 2023 1.41 0.07 5.22% 1.34 1.41 1.34
    Nov 30, 2023 1.36 -0.05 -3.55% 1.41 1.41 1.31
    Nov 29, 2023 1.34 0.11 8.94% 1.23 1.35 1.21
    Nov 28, 2023 1.28 0.00 0.00% 1.28 1.28 1.21
    Nov 27, 2023 1.31 0.04 3.15% 1.27 1.33 1.23
    Nov 24, 2023 1.24 0.01 0.81% 1.23 1.24 1.21
    Nov 22, 2023 1.20 0.06 5.26% 1.14 1.22 1.14
    Nov 21, 2023 1.19 -0.02 -1.65% 1.21 1.21 1.16
    Nov 20, 2023 1.21 0.06 5.22% 1.15 1.22 1.15
    Nov 17, 2023 1.19 -0.02 -1.65% 1.21 1.21 1.14
    Nov 16, 2023 1.22 -0.01 -0.81% 1.23 1.24 1.19
    Nov 15, 2023 1.26 0.03 2.44% 1.23 1.30 1.20
    Nov 14, 2023 1.29 0.07 5.74% 1.22 1.31 1.22
    Nov 13, 2023 1.24 0.02 1.64% 1.22 1.25 1.21
    Nov 10, 2023 1.25 0.02 1.63% 1.23 1.25 1.23
    Nov 9, 2023 1.31 -0.14 -9.66% 1.45 1.46 1.23

    Artelo Biosciences, Inc. Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2021 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 7.441 4.042 4.68578 3.20953 2.34349
    Selling/General/Admin. Expenses, Total 4.602 2.098 2.76636 2.11703 1.09335
    Operating Income -7.441 -4.042 -4.68578 -3.20953 -2.34349
    Interest Income (Expense), Net Non-Operating 0.002 0.006 0.0295 1.0061 0
    Net Income Before Taxes -7.437 -4.035 -4.65486 -2.17218 -2.34349
    Net Income After Taxes -7.437 -4.035 -4.65486 -2.17218 -2.34349
    Net Income Before Extra. Items -7.437 -4.035 -4.65486 -2.17218 -2.34349
    Net Income -7.437 -4.035 -4.65486 -2.17218 -2.34349
    Income Available to Common Excl. Extra. Items -7.437 -4.035 -4.65486 -2.17218 -2.34349
    Income Available to Common Incl. Extra. Items -7.437 -4.035 -4.65486 -2.17218 -2.34349
    Diluted Net Income -7.437 -4.035 -4.65486 -2.17218 -2.34349
    Diluted Weighted Average Shares 18.6754 33.4544 3.70765 2.17247 10.2202
    Diluted EPS Excluding Extraordinary Items -0.39822 -0.12061 -1.25548 -0.99987 -0.2293
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -0.39822 -0.12061 -1.25548 -0.99987 -0.2293
    Revenue 0 0 0
    Research & Development 2.839 1.944 1.91892 1.09199 1.24985
    Depreciation / Amortization 0.0005 0.00051 0.00029
    Other, Net 0.002 0.001 0.00141 0.03126
    Mar 2022 Aug 2021 Dec 2021 May 2021 Nov 2021
    Total revenue 0 0 0 0 0
    Total Operating Expense 1.946 1.88687 4.042 2.25141 2.552
    Selling/General/Admin. Expenses, Total 1.482 1.27141 2.098 1.30021 1.279
    Research & Development 0.464 0.61546 1.944 0.9512 1.273
    Operating Income -1.946 -1.88687 -4.042 -2.25141 -2.552
    Interest Income (Expense), Net Non-Operating -0.02 -0.00032 0.006 0.00098 0.003
    Other, Net 0.001 0.00054 0.001 0.00064 0.001
    Net Income Before Taxes -1.965 -1.88664 -4.035 -2.24979 -2.548
    Net Income After Taxes -1.965 -1.88664 -4.035 -2.24979 -2.548
    Net Income Before Extra. Items -1.965 -1.88664 -4.035 -2.24979 -2.548
    Net Income -1.965 -1.88664 -4.035 -2.24979 -2.548
    Income Available to Common Excl. Extra. Items -1.965 -1.88664 -4.035 -2.24979 -2.548
    Income Available to Common Incl. Extra. Items -1.965 -1.88664 -4.035 -2.24979 -2.548
    Diluted Net Income -1.965 -1.88664 -4.035 -2.24979 -2.548
    Diluted Weighted Average Shares 42.301 24.3484 33.4544 23.111 30.4407
    Diluted EPS Excluding Extraordinary Items -0.04645 -0.07749 -0.12061 -0.09735 -0.0837
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.04645 -0.07749 -0.12061 -0.09735 -0.0837
    • Annual
    • Quarterly
    2021 2021 2020 2019 2018
    Total Current Assets 10.317 24.609 2.3372 4.44259 0.39644
    Cash and Short Term Investments 10.065 24.113 2.14207 4.42397 0.33742
    Cash & Equivalents 6.629 12.162 2.14207 4.42397 0.33742
    Prepaid Expenses 0.252 0.496 0.19513 0.00834 0.03688
    Total Assets 12.635 28.251 4.37686 6.48273 0.397
    Total Current Liabilities 0.526 1.027 0.50218 1.02151 0.53197
    Payable/Accrued 0.493 0.975 0.49022 0.34886 0.52927
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.005 0.021 0.01196 0.67265 0.0027
    Total Liabilities 0.593 1.084 0.50218 1.02151 0.53197
    Total Long Term Debt 0 0 0 0 0
    Total Equity 12.042 27.167 3.87469 5.46121 -0.13497
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.025 0.042 0.00499 0.00335 0.014
    Additional Paid-In Capital 28.902 48.081 13.2716 10.2784 2.50188
    Retained Earnings (Accumulated Deficit) -16.903 -20.938 -9.46562 -4.81076 -2.63858
    Other Equity, Total 0.018 -0.018 0.06376 -0.00981 -0.01228
    Total Liabilities & Shareholders’ Equity 12.635 28.251 4.37686 6.48273 0.397
    Total Common Shares Outstanding 24.5267 42.301 4.99159 3.35362 14.0023
    Total Receivables, Net 0.00879 0.02213
    Property/Plant/Equipment, Total - Net 0.09 0.081 0.00025 0.00072 0.00056
    Property/Plant/Equipment, Total - Gross 0.00161 0.00151 0.00085
    Accumulated Depreciation, Total -0.00136 -0.00079 -0.00028
    Other Current Assets, Total 0.0015
    Intangibles, Net 2.039 2.039 2.03942 2.03942
    Short Term Investments 3.436 11.951
    Other Long Term Assets, Total 0.189 0.003
    Accrued Expenses 0.028 0.031
    Other Liabilities, Total 0.067 0.057
    Long Term Investments 1.519
    Mar 2022 Aug 2021 Dec 2021 May 2021 Nov 2021
    Total Current Assets 24.589 10.317 24.609 10.3003 25.355
    Cash and Short Term Investments 21.512 10.065 24.113 10.0523 24.841
    Cash & Equivalents 10.35 6.629 12.162 10.0523 14.047
    Prepaid Expenses 1.078 0.252 0.496 0.17547 0.514
    Other Current Assets, Total 0.07252
    Total Assets 26.704 12.635 28.251 12.3398 29.004
    Property/Plant/Equipment, Total - Net 0.073 0.09 0.081 0.00006 0.083
    Property/Plant/Equipment, Total - Gross 0.00165
    Accumulated Depreciation, Total -0.00158
    Intangibles, Net 2.039 2.039 2.039 2.03942 2.039
    Total Current Liabilities 0.875 0.526 1.027 0.42394 0.659
    Payable/Accrued 0.8 0.493 0.975 0.41894 0.59
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.043 0.005 0.021 0.005 0.038
    Total Liabilities 0.924 0.593 1.084 0.42394 0.718
    Total Long Term Debt 0 0 0 0 0
    Total Equity 25.78 12.042 27.167 11.9158 28.286
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.042 0.025 0.042 0.02315 0.042
    Additional Paid-In Capital 48.705 28.902 48.081 26.8593 47.718
    Retained Earnings (Accumulated Deficit) -22.903 -16.903 -20.938 -15.016 -19.451
    Other Equity, Total -0.064 0.018 -0.018 0.04938 -0.023
    Total Liabilities & Shareholders’ Equity 26.704 12.635 28.251 12.3398 29.004
    Total Common Shares Outstanding 42.301 24.5267 42.301 23.1491 42.301
    Short Term Investments 11.162 3.436 11.951 10.794
    Long Term Investments 0 1.519 1.524
    Other Long Term Assets, Total 0.003 0.189 0.003 0.003
    Accrued Expenses 0.032 0.028 0.031 0.031
    Other Liabilities, Total 0.049 0.067 0.057 0.059
    Total Receivables, Net 1.999
    • Annual
    • Quarterly
    2021 2021 2020 2019 2018
    Net income/Starting Line -7.437 -4.035 -4.65486 -2.17218 -2.34349
    Cash From Operating Activities -6.141 -2.667 -4.34738 -2.79268 -1.61002
    Non-Cash Items 1.54 0.938 0.34827 -0.48099 0.29
    Cash Taxes Paid 0 0 0 0 0
    Cash Interest Paid 0 0 0 0 0
    Changes in Working Capital -0.244 0.43 -0.04129 -0.14002 0.44319
    Cash From Financing Activities 14.112 18.261 1.98074 8.37743 1.38845
    Issuance (Retirement) of Stock, Net 14.119 18.262 1.97758 8.37638 1.38661
    Issuance (Retirement) of Debt, Net 0.00184
    Foreign Exchange Effects -0.045 -0.028 0.08475 0.00248 -0.01294
    Net Change in Cash 4.487 5.533 -2.28189 4.08654 -0.23535
    Cash From Operating Activities 0.0005 0.00051 0.00028
    Cash From Investing Activities -3.439 -10.033 0 -1.50069 -0.00085
    Capital Expenditures 0 -1.50069 -0.00085
    Financing Cash Flow Items -0.007 -0.001 0.00315 0.00105
    Other Investing Cash Flow Items, Total -3.439 -10.033
    Mar 2022 Aug 2021 Dec 2021 May 2021 Nov 2021
    Net income/Starting Line -1.965 -7.437 -4.035 -5.55036 -2.548
    Cash From Operating Activities -2.053 -6.141 -2.667 -4.59969 -1.926
    Cash From Operating Activities 0.00018
    Non-Cash Items 0.651 1.54 0.938 1.00886 0.575
    Cash Taxes Paid 0 0 0
    Cash Interest Paid 0 0 0
    Changes in Working Capital -0.739 -0.244 0.43 -0.05837 0.047
    Cash From Investing Activities 0.257 -3.439 -10.033 0 -8.878
    Capital Expenditures 0
    Cash From Financing Activities 0 14.112 18.261 12.5152 18.262
    Financing Cash Flow Items 0 -0.007 -0.001 -1.11504 0
    Issuance (Retirement) of Stock, Net 0 14.119 18.262 13.6303 18.262
    Foreign Exchange Effects -0.016 -0.045 -0.028 -0.00533 -0.04
    Net Change in Cash -1.812 4.487 5.533 7.91022 7.418
    Other Investing Cash Flow Items, Total 0.257 -3.439 -10.033 -8.878

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Artelo Biosciences, Inc. Company profile

    Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
    Industry: Bio Therapeutic Drugs

    505 Lomas Santa Fe, Suite 160
    92075

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    XRP/USD

    0.68 Price
    +4.250% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    44,187.25 Price
    +1.720% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading